Trillium Therapeutics Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statement of Cash Flows

In millions of USD, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Net loss for the year
Interest accretion
Change in fair value of contingent consideration
Share-based compensation
Amortization of warrant discount
Change in fair value of warrant liability
Amortization of intangible assets
Impairment of intangible assets
Depreciation of property and equipment
Deferred lease inducement
Unrealized foreign exchange loss (gain)
License agreement amendment
Adjustments for items not affecting cash
Amounts receivable
Prepaid expenses
Accounts payable and accrued liabilities
Other current liabilities
Cash used in operating activities
Net maturities of marketable securities
Purchase of property and equipment
Cash provided by investing activities
Repayment of lease liabilities
Repayment of loan payable
Issuance of warrants, net of issuance costs
Issuance of share capital, net of issuance costs
Cash provided by (used in) financing activities
Net decrease in cash and cash equivalents during the year
Preferred shares converted to common shares (note 9)
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Stock-based compensation
Remeasurement of warrant liability
Depreciation of property and equipment
Unrealized foreign exchange loss (gain)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Changes in operating assets and liabilities
Amounts receivable
Prepaid expenses
Operating lease right of use asset
Accounts payable
Accrued expenses
Operating lease liability
Net cash used in operating activities
Cash flows from investing activities
Maturities of marketable securities
Purchases of marketable securities
Purchases of property and equipment
Net cash provided by (used in) investing activities
Cash flows from financing activities
Repayment of loan payable
Exercise of stock options
Exercise of warrants
Issuance of warrants, net of issuance costs
Issuance of preferred and common stock, net of issuance costs
Net cash provided by financing activities
Impact of foreign exchange rate on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Supplemental disclosures of cash flow information:
Operating lease right-of-use assets obtained in exchange for operating lease liabilities
Cash paid for operating lease payments
Cash paid for income taxes
Reclassification of warrants from liability to equity
Fair value transfer of stock option liability to equity upon stock option exercise

Comments